Movetis wins two out of three categories at the PharmaVentures European Deals 2010 Awards

05-Oct-2010 - Movetis NV announced that it has won the European Financing Deal of the Year and the European M&A Deal of the Year at the PharmaVentures European Deals 2010 Awards. The awards recognise Movetis’ successful IPO on Euronext Brussels in December 2009, as well as the recent public tender offer by ...

Movetis starts phase III clinical trial with prucalopride in male patients with chronic constipation

28-Sep-2010 - Movetis NV announced that it has started a phase III clinical trial with prucalopride in male patients with chronic constipation. Positive results from this clinical trial programme should allow Movetis to support a regulatory application for expansion of the current label of Resolor® ...

Movetis receives authorisation to market Resolor in Switzerland

Switzerland is the 31st country where Resolor is authorised on the market

06-Aug-2010 - Movetis NV announced that it has received a letter from Swissmedic with the authorisation to market its lead product, Resolor (prucalopride), in Switzerland. Swissmedic granted marketing authorisation of Resolor 1mg and 2mg tablets on doctor’s prescription with the following statement: “Resolor ...

Movetis starts Phase III clinical trial with prucalopride in patients with opioid-induced constipation (OIC)

New trial marks first step in Movetis’ label expansion strategy for Resolor

21-May-2010 - Movetis NV announced that it has started a Phase III clinical trial with prucalopride in patients with constipation induced by opioid based pain medications. Positive results from its OIC clinical trial programme should allow Movetis to support a regulatory application for expansion of the ...

Movetis obtains EU authorisation for the commercialisation of Resolor (prucalopride)

26-Oct-2009 - Movetis announced that it has obtained approval from the European Commission for the commercialisation of its lead product Resolor (prucalopride – a 1mg and 2mg once a day oral tablet) for the symptomatic treatment of chronic constipation (CC) in women in whom laxatives fail to provide adequate ...

Movetis' second most advanced product progresses to Phase IIb trial following positive results in cirrhotic ascites

07-Jul-2008 - Movetis NV, a European specialist pharmaceutical company, announced that M0002 is progressing to phase IIb following positive results of a phase IIa multiple-dosing trial for the treatment of ascites, the accumulation of fluid in the abdomen in patients with liver cirrhosis resulting from liver ...

New class of highly selective 5-HT4 receptor agonists provides the next generation of GI treatments

04-Feb-2008 - A scientific review of the different pharmacological profiles of 5-HT4 receptor agonists published in Neurogastroenterology and Motility concludes that, due to a more selective mode of action, next-generation 5-HT4 compounds are expected to be safer and more effective treatment options for ...

Movetis Announces Start of a Phase IIa trial for M0002 in Ascites

11-Jun-2007 - Movetis NV, a Belgian biopharmaceutical company that specializes in developing compounds for gastrointestinal disorders, announced the start of a Phase-IIa multiple-dose trial with one of its lead products, M0002, an orally-active selective vasopressin antagonist that inhibits water re-absorption ...